{
    "clinical_study": {
        "@rank": "14845", 
        "arm_group": [
            {
                "arm_group_label": "eculizumab", 
                "arm_group_type": "Experimental", 
                "description": "Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "No intervention will be applied instead eculizumab infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "Study of eculizumab ability to correct the reperfusion injury of the kidney allograft."
        }, 
        "brief_title": "Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "End-Stage Renal Disease", 
            "Kidney Failure", 
            "Graft Reperfusion Injury"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency", 
                "Reperfusion Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "Based on experimental data and supportive observations in humans associating complement gene\n      upregulation with ischemic reperfusion injury, it is hypothesized that C5 cleavage is a key\n      step in the pathogenesis of ischemic reperfusion injury following transplantation. It was\n      further hypothesized that eculizumab, antibody that blocks C5 cleavage in humans will be an\n      effective prophylactic  agent to prevent ischemic reperfusion injury in high risk\n      recipients. For testing this hypothesis, this study is a pilot prospective study to test the\n      efficacy of eculizumab in preventing the development of reperfusion injury and contribute\n      graft survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age 1-80\n\n          2. weight - >6 kg\n\n          3. male or female\n\n          4. recipient of first kidney graft either from standard criteria deceased or live donor\n\n          5. end stage renal disease or congenital nephrotic syndrome -\n\n        Exclusion Criteria:\n\n          1. Blood group (ABO) incompatible transplantation\n\n          2. presence of donor-specific anti-human leukocyte antigen (HLA) antibodies\n\n          3. multiorgan transplantation\n\n          4. previous transplant\n\n          5. patients infected with HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)\n\n          6. patients with haemolytic-uraemic syndrome (HUS) -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756508", 
            "org_study_id": "Eculizumab for reperfusion"
        }, 
        "intervention": {
            "arm_group_label": "eculizumab", 
            "description": "Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion", 
            "intervention_name": "eculizumab", 
            "intervention_type": "Drug", 
            "other_name": "Soliris"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "eculizumab", 
            "kidney transplantation", 
            "reperfusion", 
            "rejection", 
            "infection"
        ], 
        "lastchanged_date": "April 5, 2013", 
        "location": {
            "contact": {
                "email": "kaabak@hotmail.com", 
                "last_name": "Michael M Kaabak, MD"
            }, 
            "contact_backup": {
                "email": "vik-kid@mail.ru", 
                "last_name": "Victor A Goryainov", 
                "phone": "926- 532-7004"
            }, 
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "zip": "119992"
                }, 
                "name": "Russian Scientfic Center of Surgery"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Eculizumab for Prevention and Treatment Reperfusion Injury in Kidney Transplantation.", 
        "overall_contact": {
            "email": "kaabak@hotmail.com", 
            "last_name": "Michael M Kaabak, professor", 
            "phone": "8-499-248-13-44"
        }, 
        "overall_contact_backup": {
            "email": "vik-kid@mail.ru", 
            "last_name": "Victor A Goryainov, doctor", 
            "phone": "8-926-532-70-04"
        }, 
        "overall_official": {
            "affiliation": "Russian Scientific Center of Surgery", 
            "last_name": "Michael M Kaabak, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russian Federation: Federal Service on Surveillance in Healthcare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The speed of the graft surface warming in the range 15-20\u00b0C is accessed on the the infrared video record, taken during graft reperfusion by Nec Thermo Tracer.", 
                "measure": "speed of the graft warming", 
                "safety_issue": "No", 
                "time_frame": "at the time of engraftment"
            }, 
            {
                "description": "initial graft function will be accessed daily during the first week post Tx and measured as follows:\nthe rate of serum creatinine decrease expressed as percent per day, where 100% will be the creatinine on the day before;\nintragraft blood flow by Doppler indexes (acceleration, resistance) and blood flow velocity on the three levels - main, interlobar and arcuate  arteries;", 
                "measure": "initial graft function", 
                "safety_issue": "No", 
                "time_frame": "first week after Tx"
            }
        ], 
        "reference": {
            "PMID": "23348894", 
            "citation": "de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders ME, Schaapherder AF, Kooten Cv. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013 Mar 27;95(6):816-20. doi: 10.1097/TP.0b013e31827e31c9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756508"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Russian Academy of Medical Sciences", 
            "investigator_full_name": "Michael Kaabak", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Protocol biopsy will be obtained at one month and one year. Progression of allograft nephropathy will be compared between groups.", 
                "measure": "graft morphology changes", 
                "safety_issue": "No", 
                "time_frame": "one year after transplantation"
            }, 
            {
                "measure": "One-year graft and patient survival, as well as rejection and infection rates will be calculated", 
                "safety_issue": "Yes", 
                "time_frame": "one year after Tx"
            }
        ], 
        "source": "Russian Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Russian Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}